Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Systematic Reviews
Published in: Systematic Reviews 1/2013

Open Access 01-12-2013 | Protocol

Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol

Authors: Ting-Shuo Huang, Yu-Chiau Shyu, Robin Turner, Huang-Yang Chen, Pei-Jer Chen

Published in: Systematic Reviews | Issue 1/2013

Login to get access

Abstract

Background

Diagnosis of early-stage hepatocellular carcinoma (HCC) followed by curative resection or liver transplantation offers the best chance for long-term patient survival. Clinically, ultrasonography has suboptimal sensitivity for detecting early-stage HCC. Several serological tests including alpha-fetoprotein (AFP), the ratio of lens culinaris agglutinin-reactive alpha-fetoprotein to total AFP (AFP-L3/AFP), des-gamma carboxyprothrombin (DCP), and glypican-3 (GPC-3) have been widely investigated as diagnostic biomarkers for early-stage HCC in at-risk populations. However, these tests are not recommended for routine HCC screening. Our objective is to determine the diagnostic performance of AFP, AFP-L3/AFP, DCP, and GPC-3 for the detection of HCC, particularly early-stage tumors meeting the Milan criteria.

Methods/design

We will include cross-sectional studies that consecutively or randomly recruit target populations. We will search the Cochrane Library, Medline, Embase, Science Citation Index, and the Chinese National Knowledge Infrastructure. We will also search the MEDION and ARIF databases to identify diagnostic systematic reviews that include primary studies. Reference lists of relevant reviews will be searched for additional trials. Language restrictions will not be applied. Two reviewers will independently screen study eligibility and extract data. Methodological quality will be assessed according to the revised tool for the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). Two authors will apply the QUADAS-2 assessment to all the included studies, and any discrepancies will be resolved by the third author. The following test characteristics will be extracted into 2 × 2 tables for all included studies: true positives, false positives, true negatives, and false negatives. Study-specific estimates of sensitivity and specificity with 95% confidence intervals will be displayed in forest plots. When possible, we will use the bivariate random-effects model or the Rutter and Gatsonis hierarchical summary receiver operating characteristic model for statistical analysis. To investigate heterogeneity, we will include study designs, population characteristics, test characteristics, and types of reference standard as the study-level variables.

Discussion

Our systematic review will allow patients, clinicians, and researchers to determine the diagnostic performance of AFP, AFP-L3/AFP, DCP, and GPC-3 for the detection of early-stage HCC and the potential roles of these diagnostic biomarkers in the existing diagnostic pathways.
Systematic Review Registration: PROSPERO 2013; CRD42013003879
Literature
1.
2.
3.
Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004, 127: S35-S50. 10.1053/j.gastro.2004.09.014.CrossRefPubMed
4.
Llovet JM, Bruix J: Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol. 2000, 14: 991-1008. 10.1053/bega.2000.0143.CrossRefPubMed
5.
Ioannou GN, Perkins JD, Carithers RL: Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008, 134: 1342-1351. 10.1053/j.gastro.2008.02.013.CrossRefPubMed
6.
Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Bru C, Rodes J, Bruix J: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999, 29: 62-67. 10.1002/hep.510290145.CrossRefPubMed
7.
Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS: Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005, 41: 707-716. 10.1002/hep.20636.CrossRefPubMed
8.
Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993, 328: 1797-1801. 10.1056/NEJM199306243282501.CrossRefPubMed
9.
Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR, HALT-C Trial Group: Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005, 43: 434-441. 10.1016/j.jhep.2005.03.019.CrossRefPubMed
10.
Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, Tang ZY, Wang XW: EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008, 68: 1451-1461. 10.1158/0008-5472.CAN-07-6013.CrossRefPubMed
11.
Villanueva A, Minguez B, Forner A, Reig M, Llovet JM: Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010, 61: 317-328. 10.1146/annurev.med.080608.100623.CrossRefPubMedPubMedCentral
12.
Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR: Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009, 69: 7385-7392. 10.1158/0008-5472.CAN-09-1089.CrossRefPubMedPubMedCentral
13.
Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M: Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001, 34: 570-575. 10.1016/S0168-8278(00)00053-2.CrossRefPubMed
14.
Aoyagi Y, Suzuki Y, Isemura M, Nomoto M, Sekine C, Igarashi K, Ichida F: The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer. 1988, 61: 769-774. 10.1002/1097-0142(19880215)61:4<769::AID-CNCR2820610422>3.0.CO;2-M.CrossRefPubMed
15.
Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ: Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008, 23: 1541-1548. 10.1111/j.1440-1746.2008.05395.x.CrossRefPubMed
16.
17.
Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Kanke F, Satomura S: Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL. Cancer Sci. 2011, 102: 1025-1031. 10.1111/j.1349-7006.2011.01875.x.CrossRefPubMed
18.
Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M: Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009, 137: 110-118. 10.1053/j.gastro.2009.04.005.CrossRefPubMedPubMedCentral
19.
Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M: Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2009, 7: 104-113. 10.1016/j.cgh.2008.08.041.CrossRefPubMed
20.
Carr BI, Kanke F, Wise M, Satomura S: Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci. 2007, 52: 776-782. 10.1007/s10620-006-9541-2.CrossRefPubMed
21.
Taketa K: Alpha-fetoprotein: reevaluation in hepatology. Hepatology. 1990, 12: 1420-1432. 10.1002/hep.1840120625.CrossRefPubMed
22.
Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B: Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984, 310: 1427-1431. 10.1056/NEJM198405313102204.CrossRefPubMed
23.
Fujiyama S, Morishita T, Hashiguchi O, Sato T: Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer. 1988, 61: 1621-1628. 10.1002/1097-0142(19880415)61:8<1621::AID-CNCR2820610820>3.0.CO;2-C.CrossRefPubMed
24.
Sakizono K, Oita T, Kuroda M, Kasakura S: Development of highly sensitive assay for detection of low serum level of PIVKA-II and its clinical usefulness. Rinsho Byori. 1996, 44: 871-876.PubMed
25.
Ishijima M, Nomura F, Horikoshi A, Ohnishi K, Nakai T: Determination of PIVKA-II levels in patients with small hepatocellular carcinoma–comparison of new sensitive methods. Rinsho Byori. 1996, 44: 635-639.PubMed
26.
Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H: The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer. 1998, 82: 1643-1648. 10.1002/(SICI)1097-0142(19980501)82:9<1643::AID-CNCR8>3.0.CO;2-B.CrossRefPubMed
27.
Sassa T, Kumada T, Nakano S, Uematsu T: Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 1999, 11: 1387-1392. 10.1097/00042737-199912000-00008.CrossRefPubMed
28.
Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R: Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol. 2000, 95: 1036-1040.PubMed
29.
Shimauchi Y, Tanaka M, Kuromatsu R, Ogata R, Tateishi Y, Itano S, Ono N, Yutani S, Nagamatsu H, Matsugaki S, Yamasaki S, Tanikawa K, Sata M: A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep. 2000, 7: 249-256.PubMed
30.
The committee for revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma: Clinical Practice Guidelines for Hepatocellular Carcinoma - The Japan Society of Hepatology 2009 update. Hepatol Res. 2010, 40 Suppl 1: 2-144. 10.1111/j.1872-034X.2010.00650.x.
31.
Song HH, Shi W, Filmus J: OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem. 1997, 272: 7574-7577. 10.1074/jbc.272.12.7574.CrossRefPubMed
32.
Reich-Slotky R, Bonneh-Barkay D, Shaoul E, Bluma B, Svahn CM, Ron D: Differential effect of cell-associated heparan sulfates on the binding of keratinocyte growth factor (KGF) and acidic fibroblast growth factor to the KGF receptor. J Biol Chem. 1994, 269: 32279-32285.PubMed
33.
Shafizadeh N, Ferrell LD, Kakar S: Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008, 21: 1011-1018. 10.1038/modpathol.2008.85.CrossRefPubMed
34.
Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T: Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol. 2006, 30: 1405-1411. 10.1097/01.pas.0000213323.97294.9a.CrossRefPubMed
35.
Liu H, Li P, Zhai Y, Qu CF, Zhang LJ, Tan YF, Li N, Ding HG: Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol. 2010, 16: 4410-4415. 10.3748/wjg.v16.i35.4410.CrossRefPubMedPubMedCentral
36.
Qiao SS, Cui ZQ, Gong L, Han H, Chen PC, Guo LM, Yu X, Wei YH, Ha SA, Kim JW, Jin ZT, Li S, Peng JR, Leng XS: Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology. 2011, 58: 1718-1724.CrossRefPubMed
37.
Bruix J, Sherman M: American Association for the Study of Liver D: Management of hepatocellular carcinoma: an update. Hepatology. 2011, 53: 1020-1022. 10.1002/hep.24199.CrossRefPubMedPubMedCentral
38.
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012, 56: 908-943.CrossRef
39.
Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA: Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009, 30: 37-47. 10.1111/j.1365-2036.2009.04014.x.CrossRefPubMed
40.
Zhang BH, Yang BH, Tang ZY: Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004, 130: 417-422.PubMed
41.
Bossuyt PM, Irwig L, Craig J, Glasziou P: Comparative accuracy: assessing new tests against existing diagnostic pathways. BMJ. 2006, 332: 1089-1092. 10.1136/bmj.332.7549.1089.CrossRefPubMedPubMedCentral
42.
43.
Leeflang MM, Bossuyt PM, Irwig L: Diagnostic test accuracy may vary with prevalence: implications for evidence-based diagnosis. J Clin Epidemiol. 2009, 62: 5-12. 10.1016/j.jclinepi.2008.04.007.CrossRefPubMed
44.
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, Group Q: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011, 155: 529-536. 10.7326/0003-4819-155-8-201110180-00009.CrossRefPubMed
45.
Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH: Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005, 58: 982-990. 10.1016/j.jclinepi.2005.02.022.CrossRefPubMed
46.
Rutter CM, Gatsonis CA: A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001, 20: 2865-2884. 10.1002/sim.942.CrossRefPubMed
47.
48.
Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM: Cochrane Diagnostic Test Accuracy Working G: Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008, 149: 889-897. 10.7326/0003-4819-149-12-200812160-00008.CrossRefPubMedPubMedCentral
49.
Deeks JJ, Macaskill P, Irwig L: The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005, 58: 882-893. 10.1016/j.jclinepi.2005.01.016.CrossRefPubMed
50.
Song F, Khan KS, Dinnes J, Sutton AJ: Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol. 2002, 31: 88-95. 10.1093/ije/31.1.88.CrossRefPubMed
Metadata
Title
Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol
Authors
Ting-Shuo Huang
Yu-Chiau Shyu
Robin Turner
Huang-Yang Chen
Pei-Jer Chen
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2013
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/2046-4053-2-37

Other articles of this Issue 1/2013

Systematic Reviews 1/2013 Go to the issue

Protocol

The effectiveness and cost-effectiveness of shared care: protocol for a realist review

Protocol

Structured sedation programs in the emergency department, hospital and other acute settings: protocol for systematic review of effects and events

Protocol

Understanding success and failure in multimorbidity: protocol for using realist synthesis to identify how social learning and workplace practices can be optimised

Methodology

Data extraction from machine-translated versus original language randomized trial reports: a comparative study

Research

Automated dose dispensing service for primary healthcare patients: a systematic review

Protocol

Understanding interventions for improving routine immunization coverage in children in low- and middle-income countries: a systematic review protocol